AR020329A1 - A SUBSTANCE, IN PARTICULAR A RIBOZIMA, IS ABLE TO INHIBIT THE PRESENILINE EXPRESSION 2, A RECOMBINATING MOLECULA OF DNA THAT CODIFY SUCH RIBOZIMA, A RECOMBINATING UNVECTOR THAT UNDERSTANDS THE CORRECTING CELL TO A RIBO BELLING ONE. - Google Patents

A SUBSTANCE, IN PARTICULAR A RIBOZIMA, IS ABLE TO INHIBIT THE PRESENILINE EXPRESSION 2, A RECOMBINATING MOLECULA OF DNA THAT CODIFY SUCH RIBOZIMA, A RECOMBINATING UNVECTOR THAT UNDERSTANDS THE CORRECTING CELL TO A RIBO BELLING ONE.

Info

Publication number
AR020329A1
AR020329A1 ARP990103296A ARP990103296A AR020329A1 AR 020329 A1 AR020329 A1 AR 020329A1 AR P990103296 A ARP990103296 A AR P990103296A AR P990103296 A ARP990103296 A AR P990103296A AR 020329 A1 AR020329 A1 AR 020329A1
Authority
AR
Argentina
Prior art keywords
ribozymes
ribozyme
ribozima
recombinating
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP990103296A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR020329A1 publication Critical patent/AR020329A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen sustancias capaces de inhibir la expresion de presenilina 2 en enfermedades neurodegenerativas, en particular en la enfermedad de Alzheimer.Estas sustancias son, en particular, ribozimas capaces de segmentar el RNA específico de la presenilina 2. Preferentemente, dichas ribozimas son ribozimas defusion que comprenden una ribozima específica de la presenilina 2 y una ribozima autocatalítica en cabeza de martillo. También se describen moléculas de DNArecombinante que codifican dichasribozimas, un vector recombinante que comprende el cDNA correspondiente a dichas ribozimas y una célula hospedadora quecomprende dicho vector recombinante. Asimismo se describen composiciones farmacéuticas que contienen dicha sustancia o ribozima o molécula de ADN o dichovector recombinante y un vehículo farmacéuticamente aceptable. También se describe el uso de dicha sustancia o ribozima o molécula de ADN o dicho vectorrecombinante en la elaboracion de un medicamento para el tratamiento de enfermedades neurovegetativas. Finalmente se describe un procedimiento para laproduccion de la ribozima como la mencionada más arriba, en el cual se sintetiza en un sintetizador automático una molécula de DNA como la mencionada másarriba. De esta manera,se proporcionan sustancias para reducir la muerte celular neuronal debida a la apoptosis, las cuales pueden ser empleadas para tratarenfermedades neurodegenerativas, en particular, en particular, la enfermedad de Alzheimer. A diferencia de los tratamientos tan solo sintomáticos existentes enel estado de la técnica, estas sustancias permiten llevar a cabo un tratamiento modificador de la enfermedad que haga frente a la patología de la misma.Substances capable of inhibiting the expression of presenilin 2 in neurodegenerative diseases are described, in particular in Alzheimer's disease. These substances are, in particular, ribozymes capable of segmenting the specific RNA of presenilin 2. Preferably, said ribozymes are defusion ribozymes that they comprise a specific ribozyme of presenilin 2 and a hammerhead autocatalytic ribozyme. Also described are DNArecombinant molecules encoding said ribozymes, a recombinant vector comprising the cDNA corresponding to said ribozymes and a host cell that comprises said recombinant vector. Also described are pharmaceutical compositions containing said substance or ribozyme or recombinant DNA molecule or said vector and a pharmaceutically acceptable carrier. The use of said substance or ribozyme or DNA molecule or said vectorrecombinant in the preparation of a medicament for the treatment of neurovegetative diseases is also described. Finally, a procedure for the production of ribozyme as described above is described, in which a DNA molecule such as the above-mentioned one is synthesized in an automatic synthesizer. In this way, substances are provided to reduce neuronal cell death due to apoptosis, which can be used to treat neurodegenerative diseases, in particular, in particular, Alzheimer's disease. Unlike the only symptomatic treatments existing in the state of the art, these substances allow to carry out a modifying treatment of the disease that addresses the pathology of the same.

ARP990103296A 1998-07-09 1999-07-07 A SUBSTANCE, IN PARTICULAR A RIBOZIMA, IS ABLE TO INHIBIT THE PRESENILINE EXPRESSION 2, A RECOMBINATING MOLECULA OF DNA THAT CODIFY SUCH RIBOZIMA, A RECOMBINATING UNVECTOR THAT UNDERSTANDS THE CORRECTING CELL TO A RIBO BELLING ONE. Pending AR020329A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98112653 1998-07-09
US12620099P 1999-03-25 1999-03-25

Publications (1)

Publication Number Publication Date
AR020329A1 true AR020329A1 (en) 2002-05-08

Family

ID=45569968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103296A Pending AR020329A1 (en) 1998-07-09 1999-07-07 A SUBSTANCE, IN PARTICULAR A RIBOZIMA, IS ABLE TO INHIBIT THE PRESENILINE EXPRESSION 2, A RECOMBINATING MOLECULA OF DNA THAT CODIFY SUCH RIBOZIMA, A RECOMBINATING UNVECTOR THAT UNDERSTANDS THE CORRECTING CELL TO A RIBO BELLING ONE.

Country Status (6)

Country Link
EP (1) EP1095138A2 (en)
JP (1) JP2002520016A (en)
AR (1) AR020329A1 (en)
AU (1) AU5033999A (en)
CA (1) CA2332497A1 (en)
WO (1) WO2000003004A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040385A1 (en) 1996-04-25 1997-10-30 Bioarray Solutions, Llc Light-controlled electrokinetic assembly of particles near surfaces
US20030027126A1 (en) 1997-03-14 2003-02-06 Walt David R. Methods for detecting target analytes and enzymatic reactions
US7622294B2 (en) 1997-03-14 2009-11-24 Trustees Of Tufts College Methods for detecting target analytes and enzymatic reactions
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
JP2003012548A (en) * 2001-06-27 2003-01-15 Japan Science & Technology Corp Medicine composition
JP4377689B2 (en) 2001-10-15 2009-12-02 バイオアレイ ソリューションズ リミテッド Combined analysis of polymorphic loci with simultaneous interrogation and enzyme-mediated detection
WO2004047007A1 (en) 2002-11-15 2004-06-03 Bioarray Solutions, Ltd. Analysis, secure access to, and transmission of array images
JP4564959B2 (en) 2003-09-22 2010-10-20 バイオアレイ ソリューションズ リミテッド Surface-immobilized polyelectrolyte with multiple functional groups that can be covalently bonded to biomolecules
CA2899287A1 (en) 2003-10-28 2005-05-12 Bioarray Solutions Ltd. Optimization of gene expression analysis using immobilized capture probes
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4203441C1 (en) * 1992-02-06 1993-10-14 Max Planck Gesellschaft RNA and DNA molecules to create virus resistance
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5700923A (en) * 1994-09-29 1997-12-23 Hybridon, Inc. Finderons and methods of their preparation and use
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
AU3005697A (en) * 1996-05-13 1997-12-05 Hybridon, Inc. Ribozyme variants with improved catalytic activity under low magnesium conditions
WO1997046678A1 (en) * 1996-06-06 1997-12-11 Bayer Corporation Nucleic acids and polypeptides related to presenilin
US6300483B1 (en) * 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs

Also Published As

Publication number Publication date
EP1095138A2 (en) 2001-05-02
AU5033999A (en) 2000-02-01
CA2332497A1 (en) 2000-01-20
WO2000003004A3 (en) 2000-04-20
JP2002520016A (en) 2002-07-09
WO2000003004A2 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
Shoyab et al. Structure and function of human amphiregulin: a member of the epidermal growth factor family
Nobori et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
RU95110938A (en) Derivatives of 1-(2-oxoacetyl)pyperidine-2-carboxylic acids, pharmaceutical composition, method of treatment, method for production
AR020329A1 (en) A SUBSTANCE, IN PARTICULAR A RIBOZIMA, IS ABLE TO INHIBIT THE PRESENILINE EXPRESSION 2, A RECOMBINATING MOLECULA OF DNA THAT CODIFY SUCH RIBOZIMA, A RECOMBINATING UNVECTOR THAT UNDERSTANDS THE CORRECTING CELL TO A RIBO BELLING ONE.
UY23561A1 (en) PROCEDURE FOR THE PREPARATION OF TNF-MUTEINS
JPH01500199A (en) Wound healing and bone regeneration
CA2067744A1 (en) The human c3b/c4b receptor (cr1)
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
EP0797999A3 (en) Formulations of obesity protein
RU94042935A (en) Water-soluble complexes of benzothiophene compounds incorporation with water-soluble cyclodextrines, method of their preparing and pharmaceutical composition
AR013529A1 (en) RANTES AMINO-TERMINALLY TRUNCATED, DNA MOLECULES, VECTOR OF EXPRESSION, GUEST CELL, RECOMBINANT PROCESS TO PREPARE IT, ITS USE TO PREPARE A MEDICINAL PRODUCT AND COMPARISON THAT UNDERSTANDS IT.
ATE537834T1 (en) 2-METHYLENE-19-NOR-VITAMIN D2 COMPOUNDS
Liu et al. Bioinspired Andrias davidianus-Derived wound dressings for localized drug-elution
EP1597271B1 (en) Peptides directed against antibodies, which cause cold-intolerance, and the use thereof
EP0685490A1 (en) Process for the purification of homogeneous platelet-derived endothelial cell growth factor from a platelet lysate
JPH10310534A (en) Composition for treating wound and use of peptide
CN1183961C (en) Remedies for bone metabolic errors
WO1986005180A1 (en) Novel tannin composition
JP2002512018A (en) Matrix binding factor
JPS61155324A (en) Anticancer drug and remedy
EP0371195B1 (en) Process for producing preparations containing acitve peptides suited for rectal and vaginal application
Rehana et al. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus
DE2442995A1 (en) PROTEASE-FREE KALLIKREIN SOLUTIONS, A PROCESS FOR THEIR PRODUCTION FROM PURIFIED KALLIKREIN AND THEIR USE AS A MEDICINAL PRODUCT
AR006214A1 (en) A METHOD FOR MOBILIZING CELLS THROUGH HIALURONAN (HA) TREATMENT
KR20130046702A (en) Novel whitening compound and whitening cosmetic composition comprising the same